

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences Appointed Anders Elm Pedersen, MD, PhD, DMSc, as Senior Medical Director to accelerate further the Global Clinical Development progress

NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead the clinical strategy and clinical development plans of the Company's ever-growing pipeline. Anders brings extensive research, clinical development and medical affairs experience to NMS, and authored more than 80 research publications within preclinical and clinical research

"We are super excited to have Anders join our team at NMS's crucial development phase, as we are advancing several key clinical programs with accelerated pace and building a strong team to support this progress," said Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer of NMS Srl and CEO and MD of NMS-US. "With his clinical development and medical affairs background and proven track record of success, Anders will bring invaluable expertise to lead this growing team."

Dr. Pedersen commented: "I am honored to join NMS to work alongside Lisa and colleagues in Italy and the US at this transformational stage of the Company. The company is developing multiple assets with first-in-class potential and I look forward to advancing them with the team to address high unmet medical needs and improve patient lives."

Dr. Pedersen's most recent position was Director of Early Development and Translational Medicine at Ammirall, where he had oversight off clinical trials and led clinical study design and clinical development plans. Also, he contributed translational medicine strategy across drug development stages as well as providing medical advice in relation to licensing opportunities. Previously he was Head of Medical Affairs at Merck, Denmark leading research and medical affairs activities within Neurology & Immunology (Multiple sclerosis), Fertility (Assisted reproductive technology) and Immuno-Oncology. His experience also extended to the academic world as associate professor and group leader of "Translational Immunology Group" at University of Copenhagen with a focus on drug development.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](https://www.nervianoms.com) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing). A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it